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Current guidelines recommend immunosuppressive treatment (IT) in patients with primary
sclerosing cholangitis (PSC) and elevated aminotransferase levels more than five times the
upper limit of normal and elevated serum IgG-levels above twice the upper limit of normal.
Since there is no evidence to support this recommendation, we aimed to assess the criteria
that guided clinicians in clinical practice to initiate IT in patients with previously diagnosed
PSC.
Methods
This is a retrospective analysis of 196 PSC patients from seven German hepatology cen-
ters, of whom 36 patients had received IT solely for their liver disease during the course of
PSC. Analyses were carried out using methods for competing risks.
Results
A simplified autoimmune hepatitis (AIH) score >5 (HR of 36, p<0.0001) and a modified
histological activity index (mHAI) greater than 3/18 points (HR 3.6, p = 0.0274) were associ-
ated with the initiation of IT during the course of PSC. Of note, PSC patients who
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subsequently received IT differed already at the time of PSC diagnosis from those patients,
who did not receive IT during follow-up: they presented with increased levels of IgG (p =
0.004) and more frequently had clinical signs of cirrhosis (p = 0.0002).
Conclusions
This is the first study which investigates the parameters associated with IT in patients with
PSC in clinical practice. A simplified AIH score >5 and a mHAI score >3, suggesting con-
comitant features of AIH, influenced the decision to introduce IT during the course of PSC.
In German clinical practice, the cutoffs used to guide IT may be lower than recommended
by current guidelines.
Introduction
Primary sclerosing cholangitis (PSC) is a chronic and progressive inflammatory disease of
the intra- and/or extrahepatic bile ducts leading to end stage liver disease, transplantation or
death within 10–20 years. PSC is associated with dysregulated immune reactions, and acti-
vated T-cells can be found in the livers of these patients.[1, 2] This immune imbalance may
be a general feature of PSC; however a subgroup of patients can present with or will develop
typical features of additional autoimmune hepatitis (AIH) during the course of their disease
[also termed overlap syndrome (OS)]. Whereas most experts agree that PSC patients with
features of AIH could benefit from immunosuppressive treatment (IT), no consensus has
been reached on how to identify these rare patients. The decision to introduce IT in PSC is
especially difficult in patients who present with classical PSC at first sight and develop fea-
tures of increased liver inflammation during the course of their disease. An elevation of
serum aminotransferase levels above 5x the upper limit of normal (ULN) and an elevation of
serum IgG levels above 2x the ULN have been proposed as diagnostic features pointing
towards additional AIH, which should then lead to additional IT.[3] However, in clinical
practice most physicians tend to initiate IT at lower serum levels of aminotransferases and
IgG.
Liver histology is mandatory to diagnose AIH in patients without PSC, but it is unknown
which grade of liver inflammation in PSC indicates additional AIH or an inflammatory activity
of PSC which should prompt additional IT.[4] Moreover, given the hypothesis that suppression
of liver inflammation could reduce disease progression, it may be important to identify patients
at high risk of an inflammatory course of the disease already at diagnosis.
Patients who present with or will develop typical features of AIH during the course of
their disease represent rare variants and data on the management of these patients is scarce.
Moreover, to date a generally accepted definition of features justifying the additional diag-
nosis of AIH or indicating liver inflammation that exceeds the degree which is normally
seen in PSC is lacking. Since prospective trials will be very difficult to perform in this group
of patients we–in a first step–aimed to investigate parameters associated with the introduc-
tion of IT in real life treatment in several German hepatology centers. By the identification
of factors guiding clinicians in practice to introduce IT in PSC, it may be possible to identify
a subpopulation of patients qualifying for future clinical trials on immunomodulatory
treatment.
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Patients and Methods
Patients
Since the aim of this study was to identify parameters associated with the initiation of IT in
patients with previously diagnosed PSC in clinical practice, records of 218 patients with estab-
lished PSC were reviewed between the years 1986 and 2012 at seven university medical centers
in Germany. The diagnosis of PSC was established according to accepted criteria using endo-
scopic retrograde cholangiography (ERC) and/or magnetic resonance cholangio-pancreatico-
graphy (MRCP) as described in the European association for the study of the liver (EASL)
clinical practice guidelines.[5] Patients with the small duct variant were not included leading to
the exclusion of 2 patients due to a normal cholangiogram. Although it is current standard in
Germany to treat all PSC patients with ursodeoxycholic acid (UDCA) at a dose of 15–20 mg/kg
body weight, 3 patients had to be excluded because of lacking information on UDCA treatment
after PSC diagnosis and 8 patients did not receive UDCA during follow-up. Since patients with
a simultaneous diagnosis of PSC and AIH were not included into this study, another 3 patients
had to be excluded.
Six additional patients, who had a follow-up of less than 12 weeks after the diagnosis of
PSC, were excluded. To reach our principal aim, the retrospective cohort is hence formed by
196 PSC patients.
In all patients, the prescription of UDCA is considered to coincide with the time point of
diagnosis and this is the starting point for our subsequent analyses. Laboratory and serological
parameters were assessed at the start of UDCA treatment and before the start of IS treatment
(steroids and/or azathioprine) by standard methods. Among the 196 patients in our cohort, 36
patients were identified who received IT specifically directed towards their liver disease at least
12 weeks after the diagnosis of PSC were identified. These patients will be termed PSC-IT for
the purpose of this manuscript.
The presence or absence of inflammatory bowel disease (IBD) was assessed using colonos-
copy, and signs of liver cirrhosis (ascites, splenomegaly, and/or esophageal varices) were
recorded. Viral hepatitis was excluded serologically. The simplified AIH score, a diagnostic tool
to measure the probability of underlying AIH (6 points probable,7 points definite AIH) in
patients with liver disease, was calculated considering following parameters: ANA or SMA1:40
1 point; ANA or SMA1:80 or LKM1:40 or SLA positive 2 points; IgG>upper normal limit
1 point; IgG>1.10 times upper normal limit 2 points; liver histology compatible with AIH 1
point; liver histology typical for AIH 2 points; absence of viral hepatitis 1 point.[6] Since patient
acquisition dates back many years, serum IgG4-levels were not available for analysis.
Liver histology
Liver tissue of 36 classical PSC patients and 16 PSC-IT patients was available for re-analysis by
an expert liver pathologist who was blinded to patient's treatment status. These samples were
obtained at diagnosis of PSC and before the start of IT, and examined for the presence of fea-
tures of AIH as well as PSC. Histological activity was graded according to the modified hepatic
activity index (mHAI) and staged according to the criteria of Ludwig.[7, 8] The following histo-
logical features were investigated to indicate PSC: bile duct damage, bile duct basement mem-
brane thickening, periductal concentric fibrosis, ductopenia / fibro-obliterative scars, ductular
reaction, periportal copper deposition, and metaplastic CK7-positivity of periportal hepato-
cytes. The following histological features were investigated to indicate AIH: portal inflamma-
tion, lymphoplasmocytic infiltrate, interface activity, lobular inflammation, rosette formation,
and emperipolesis.[6]
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Statistical analysis
The general aim of the present cohort study was to investigate whether clinical, biochemical, or
histological data were associated with the initiation of IT during the PSC disease course.
Patient's time under risk for the initiation of IT started at first UDCA prescription and
ended at start of IT, liver transplantation, death, or end of follow-up. Since starting the IT
implies survival and no transplantation beforehand, analyses were carried out using methods
for competing risks.[9] Hence, figures on the initiation of IT indicate the cumulative probabil-
ity receiving IT in the present of competing risks considering relevant cut-off values. Patient’s
characteristics of at least ordinal level were described using the median accompanied by the
first (Q1) and the third quartile (Q3).
As this study is exploratory by nature, no correction for multiple testing was carried out,
and a p-value less than 0.05 was considered to be statistically significant. Underlying raw data
is included in the supporting information (S1 Table). The study protocol was approved by the
Ethics Committee of the Hamburg Medical Association and the patient records were anon-
ymized and de-identified prior to analysis.
Results
Patient population
The study population consisted of 196 PSC patients of whom 36 received IT. The median fol-
low-up period until liver transplantation, death or censoring of the 196 patients was 3.5 years
(Q1: 1.7 years, Q3: 7.6 years). In PSC patients who received IT during the course of their dis-
ease, IT was started a median time of 2.7 years (Q1: 1.6 years, Q3: 6.0 years) after PSC
diagnosis.
Patient characteristics at first presentation
The median age at PSC diagnosis was 34 years and 65% of patients were male. Although one
might expect that younger patients present with a more inflammatory course of PSC, in this
analysis age at diagnosis (29 years) did not appear to be associated with subsequent IT. Gender
was also not associated with IT (p = 0.77). IBD was present in 48% of all 196 patients at PSC
diagnosis, but after screening by colonoscopy, 59% of PSC-IT patients and 67% of all other
patients had an IBD-diagnosis. The presence of IBD during follow-up was not significantly
associated with IT (p = 0.68). And finally, the ratio between ALT and AP>2.5 with respect to
normal values was not significantly different in patients receiving IT in the course of the dis-
ease. Table 1 summarizes the clinical characteristics of the cohort.
Parameters associated with immunosuppressive treatment in patients
with PSC
Histological hepatitis activity. Histological findings are key to the diagnosis of classical
AIH and histological disease activity scores are used by many experts to guide IT. We therefore
assessed the severity of hepatitis as measured by the mHAI. For this purpose we were able to
reassess liver biopsies obtained at diagnosis of PSC for a subset of 52 out of the 196 patients.
Among these patients, 16 received IT. Table 2 summarizes the histological findings in both
groups of patients. Twelve out of 52 histological samples demonstrated mHAI scores of more
than 3/18 points. Eleven of these 12 cases subsequently received IT during the course of disease.
Of the remaining 40 cases (mHAI less or equal than 3 points), only 5 patients were treated with
IT during the observation period. Thus, taking the mHAI score as a probability factor into
account, the cut-off value of only 3 points was significantly associated with the introduction of
PSC and Immunosuppressive Treatment
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IT during the disease course of PSC [hazard ratio (HR) 3.6, p = 0.0274, Table 3]. Fig 1 high-
lights two typical liver histologies of patients with a mHAI score greater and lower than 3
points.
Simplified AIH score. The simplified AIH score can be used in clinical practice to aid the
diagnosis of classical AIH.(6) Hence, we evaluated whether this score was associated with sub-
sequent IT in patients with PSC. Using a cut-off value of more than 5 points–determining a
Table 1. Univariate analysis of potential risk factors for IT as first event after UDCA prescription (using Cox' model) at first presentation.
State at the end of follow-up PSC-IT PSC 95% Confidence Interval p-Value
Hazard Ratio Lower Limit Upper Limit
All patients [N] 36 160
Median age [Years]: 35 35
Age groups [N, (%)]:
[4–25 years) 13 (36.1) 29 (18.1) 1.7 0.8 3.6 0.19
[25–40 years) 13 (36.1) 72 (45.0)
[40–72 years] 10 (27.8) 59 (36.9) 1.2 0.5 2.8 0.63
Sex [N (%)]:
male 24 (66.7) 104 (63.8) 0.9 0.5 1.8 0.77
female 12 (33.3) 56 (36.2)
IBD [N (%)] 20* (58.8) 100* (66.7) 0.9 0.4 1.7 0.68
Ulcerative colitis 18 (90.0) 68 (68.2)
Crohn’s disease 2 (10.0) 18 (18.0)
Indeterminate colitis - 14 (14.0)
ALT vs. AP Ratio >2.5 times [N (%)]: - 6 (4.0) 0.0 0.0 . 0.99
Clinical signs of cirrhosis [N (%)]: 23 (69.7) 37 (29.4) 4.1 2.0 8.7 < 0.01
* = after first screening by colonoscopy
doi:10.1371/journal.pone.0140525.t001
Table 2. Histological characteristics in patients with and without IT.
PSC-IT [n = 16] PSC [n = 36]
Patients [N (%)] Median (Q1, Q3) Patients [N (%)] Median (Q1, Q3)
Patients: 16 (31) 36 (69)
Fibrosis [Grade 1–6]: 4 (2, 5) 2 (1, 3)
Concentric fibrosis: 7 (44) 21 (58)
mHAI Score* [0–18]: 4 (3, 6) 1 (1, 2)
A [0–4] 1 (1, 1) 0 (0, 0)
B [0–6] 0 (0, 0) 0 (0, 0)
C [0–4] 1 (1, 2) 0 (0, 1)
D [0–4] 2 (2, 2) 1 (1, 1)
Histological diagnosis of PSC/AIH overlap:
No 4 (25) 35 (97)
Probable 7 (44) 1 (3)
Typical 5 (31) 0 (0)
Presence of pseudorosettes: 12 (75) 24 (67)
* A: periportal or periseptal interface hepatitis (piecemeal necrosis); B: confluent necrosis; C: focal lytic necrosis, apoptosis, and focal inflammation; D:
portal inflammation.
doi:10.1371/journal.pone.0140525.t002
PSC and Immunosuppressive Treatment
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probable or definite AIH diagnosis in patients with chronic hepatitis–the simplified AIH score
was demonstrating the strongest association to the subsequent initiation of IT in patients with
PSC (HR 36, p<0.0001, Table 3). In total, 68% of patients with a simplified AIH score of more
than 5 points received IT for their liver disease during the course of the observation period.
Parameters at the time of PSC diagnosis which were associated with
subsequent immunosuppressive treatment
Laboratory values and presence of cirrhosis at the time of PSC diagnosis. Next, we were
interested whether laboratory values already at the time of PSC diagnosis were associated with
the subsequent introduction of IT in patients with PSC. To this end, biochemical markers of
cholestasis as well as hepatitis activity were analyzed (Table 4).
In patients with established AIH, serum IgG levels were described to correlate with histolog-
ical disease activity.[10] In our PSC cohort, using a cut-off value of 16 g/L ULN, IgG at the time
of initial presentation was associated with IT during the course of disease: among patients with
IgG levels above 16 g/L at PSC diagnosis, 31% received this treatment during follow-up (HR
5.3, p = 0.0046, Fig 2), suggesting an increased hepatitis activity in these patients already at the
time of PSC diagnosis.
Patients with higher hepatic inflammatory activity may more rapidly develop liver fibrosis
and present a higher rate of liver cirrhosis at PSC diagnosis. Indeed, signs of liver cirrhosis at
PSC diagnosis were associated with an increased probability of subsequent IT (HR = 4.1,
p = 0.0002).
Serum bilirubin levels above 1.2 mg/dL (ULN, Fig 2) as well as an ALT value of more than
70 U/L (2x ULN) tended to be associated with a higher probability for the introduction of IT
during the course of disease (p = 0.05 each, Table 4). The frequency of autoantibody titers was
not significantly higher in patients with IT, but they were infrequently available at the time of
PSC diagnosis (p = 0.128). Markers of cholestasis, such as levels of serum alkaline phosphatase
or γ-glutamyltransferase, were not found to be associated with subsequent IT. Fig 2 displays
the cumulative probability receiving IT during the course of PSC depending on laboratory
findings at the time of PSC diagnosis.
Discussion
PSC can present with varying degrees of liver inflammation, in few patients fulfilling diagnostic
criteria of classical AIH. To date, it remains undetermined, which degree of liver inflammation
is acceptable for the sole diagnosis of PSC and what defines the need for additional IT. In cur-
rent guidelines, it is recommended that a cut-off of ALT levels more than five times the ULN
Table 3. Histological disease activity and simplified AIH score as single risk factors for IT in patients with PSC.
Complete Cohort PSC-IT Cohort 95% Confidence Interval p-Value
Patients [N (%)] Patients [N (%)] Hazard Ratio Lower Limit Upper Limit Cox
mHAI Score 52 (100) 16 (100) 0.03
3 points 40 (77) 5 (31)
>3 points 12 (23) 11 (69) 3.6 1.2 11.1
Simplified AIH Score* 122 (100) 17 (100) <0.0001
 5 points 100 (82) 2 (11)
> 5 points 22 (18) 15 (89) 36.4 8.3 159.7
* Including patients with/without histological assessment considering maximum points of histological score still leading to  5 points.
doi:10.1371/journal.pone.0140525.t003
PSC and Immunosuppressive Treatment
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and IgG levels above twice the ULN should lead to IT.[3] We here aimed to assess parameters,
which prompted the addition of IT during the course of PSC in real life, since we had the
impression that in clinical practice, IT is initiated at lower cut-offs than given in guidelines.
Although this study was not designed to show whether IT was beneficial for the patients who
had received it, the results may help to define patients with PSC who could be included in clini-
cal trials on immunomodulatory treatment.
We here demonstrate that serum IgG levels and the frequency of liver cirrhosis differed
already at the time of PSC diagnosis in patients who later received IT. Assuming that early sup-
pression of liver inflammation may slow the progression of the disease; these findings may
have practical implications for the early detection of patients at risk. The strongest parameter
associated with initiation of IT during the course of PSC was the simplified AIH score which
represents a combination of typical features of AIH, including liver histology. Although this in
itself may not be surprising it is important to note that the cut-offs proposed in guidelines with
regard to ALT serum levels were not associated with IT in this study.
Fig 1. Liver histologies of PSC patients with a mHAI score greater and lower than 3 points. A: typical
concentric fibrosis and low grade of inflammation. B: typical periductular fibrosis and additionally signs of
interface hepatitis (*), representing a patient with a mHAI score of 8/18. Staining: hematoxylin eosin.
doi:10.1371/journal.pone.0140525.g001
Table 4. Laboratory values at the time of PSC diagnosis and the association with the subsequent introduction of IT during the course of PSC.
Complete Cohort PSC-IT 95% Confidence Interval p-Value
Patients* [N* (%)] Patients* [N* %)] Hazard Ratio Lower Limit Upper Limit
AP, Cut-off 200 U/L 147 (100) 18 (100)
 53 (36) 3 (17)
> 94 (64) 15 (83) 2.0 0.6 7.0 0.29
yGT, Cut-off 200 U/L 152 (100) 20 (100)
 69 (45) 6 (30)
> 83 (55) 14 (70) 2.4 0.9 6.3 0.07
Bilirubin, Cut-off 1.2 mg/dL 144 (100) 19 (100)
 94 (65) 7 (37)
> 50 (35) 12 (63) 2.6 1.0 6.6 0.05
AST, Cut-off 70 U/L 102 (100) 12 (100)
 75 (74) 6 (50)
> 27 (26) 6 (50) 2.4 0.8 7.3 0.14
ALT, Cut-off 70 U/L 149 (100) 20 (100)
 71 (48) 5 (25)
> 78 (52) 15 (75) 2.7 1.0 7.5 0.05
IgG, Cut-off 16 g/L 101(100) 15 (100)
 66 (65) 4 (27)
> 35 (35) 11 (73) 5.3 1.7 16.5 <0.01
At least one positive Auto-AB-titer 82 (100) 8 (100)
– 33 (40) 2 (25)
+ 49 (60) 6 (75) 3.6 0.7 18.4 0.13
Creatinine, Cut-off 0.8 mg/dL 136 (100) 18 (100)
 90 (66) 10 (56)
> 46 (34) 8 (44) 2.7 1.1 7.1 0.04
* Patients with values available at the time of PSC diagnosis
doi:10.1371/journal.pone.0140525.t004
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The study presented here has several strengths and obvious shortcomings. A limitation of
the present study is the retrospective cohort compilation reaching back until the 1980s, which
led to missing clinical data in some of the patients, including serum IgG4 levels, which should
be determined at diagnosis of PSC.[3] Also, by study design, the prevalence of patients treated
with IT cannot be calculated from this set of data. Most importantly, as mentioned above, this
study was not intended to provide evidence for a beneficial effect of IT in inflammatory type of
PSC. To our knowledge, this is the largest study to date investigating parameters leading to
liver-directed IT in patients with known PSC. The multicenter design should in part correct for
individual physician´s preferences in prescribing this treatment, and the patient collective rep-
resents a typical PSC cohort including a typical age at diagnosis, IBD prevalence, as well as
male predominance of 65%.[5]
This multicenter experience suggests that clinical practice, at least in Germany, is different
to what is suggested in guidelines, taken into consideration that the latest position statement of
the International Autoimmune Hepatitis Group (IAIHG) suggested an at least five-fold eleva-
tion of aminotransferase levels and a more than two-fold elevation of serum IgG levels as
Fig 2. Cumulative probability of introduction of IT in the presence of competing risks at the time of PSC diagnosis (start of UDCA prescription):
Alkaline phosphatase (AP), bilirubin, alanine aminotransferase (ALT), immunoglobulin G (IgG).
doi:10.1371/journal.pone.0140525.g002
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features which should lead to additional IT [3, 5, 11]: In the group of 36 PSC-IT patients
described here, the median serum IgG level was 23 g/l and the median ALT level was 111 U/l at
the time of PSC diagnosis (data not shown).
Scoring systems developed for AIH have been applied to assess the frequency of AIH features
in PSC populations.[3, 12–15] These studies demonstrated that features yielding a “definite”AIH
diagnosis in patients with PSC patients are rare. Depending on the population analyzed, the origi-
nal, the revised and, recently also the simplified AIH score identified less than 5% of PSC patients
as also harboring typical AIH features.[16] It should be underlined that these scoring systems,
especially the original and revised scoring systems, were not developed to differentiate AIH from
variant syndromes, such as overlap with PSC or primary biliary cirrhosis, and have not been rec-
ommended for this purpose.[3, 17] Nevertheless, in this study it was interesting to see that the
simplified AIH score seemed to guide clinicians towards IT, since the hazard to receive IT was 36
times increased for patients with a simplified AIH score of more than 5 points, indicating per def-
inition probable or definite AIH.[6] As a word of caution, liver biopsies could be reviewed in a
standardized fashion in 52 patients only and therefore the simplified AIH score could be calcu-
lated only for a subset of patients who were not drawn at random from the entire cohort.
Liver histology is an essential part of AIH diagnosis and included in the simplified AIH
score.[6] The indication to obtain a liver biopsy is individualized and it is not a routine proce-
dure advised in PSC patients in the current guidelines.[5, 11] However, from the guidelines it
remains unclear which PSC patients should undergo liver biopsy in order to assess inflamma-
tory activity. In this study, a mHAI score of more than three points was associated with a
three-fold higher risk to subsequently receive IT. Although there is no evidence from controlled
clinical trials, it is argued in current guidelines and suggested from small case series that PSC
patients with features of AIH could benefit from IT.[3, 5, 11, 18] To identify these patients as
early as possible may help to improve their prognosis. The results presented here suggest that
elevated serum IgG levels and signs of liver cirrhosis at diagnosis may indicate patients at risk.
Conclusion
In conclusion, we here describe parameters which were associated with IT during the course of
PSC. To date there is no medical treatment with a proven benefit on the course of PSC. The
results of the current retrospective cohort study could help to identify patients qualifying for
clinical trials targeting liver inflammation. Additionally, since prospective controlled clinical
trials are difficult to perform in this rare patient population, the comparison of patients
included in multicenter databases with the risk factors identified herein who were or were not
treated with IT could indicate an effect of IT on the course of disease.
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